PL3202772T3 - Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2 - Google Patents

Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2

Info

Publication number
PL3202772T3
PL3202772T3 PL15846001.4T PL15846001T PL3202772T3 PL 3202772 T3 PL3202772 T3 PL 3202772T3 PL 15846001 T PL15846001 T PL 15846001T PL 3202772 T3 PL3202772 T3 PL 3202772T3
Authority
PL
Poland
Prior art keywords
proline
inhibitor
sodium
crystal
complex
Prior art date
Application number
PL15846001.4T
Other languages
English (en)
Inventor
Piaoyang Sun
Guaili Wu
Changshan GUO
Yun Lu
Yuxia Wu
Lingjia SHEN
Original Assignee
Jiangsu Hengrui Medicine Co. Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co. Ltd. filed Critical Jiangsu Hengrui Medicine Co. Ltd.
Publication of PL3202772T3 publication Critical patent/PL3202772T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04Cyclic acetals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/01Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL15846001.4T 2014-09-30 2015-09-08 Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2 PL3202772T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410523436 2014-09-30
PCT/CN2015/089128 WO2016050134A1 (zh) 2014-09-30 2015-09-08 一种钠-葡萄糖协同转运蛋白2抑制剂的l-脯氨酸复合物、其一水合物及晶体

Publications (1)

Publication Number Publication Date
PL3202772T3 true PL3202772T3 (pl) 2021-02-22

Family

ID=55629417

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15846001.4T PL3202772T3 (pl) 2014-09-30 2015-09-08 Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2

Country Status (13)

Country Link
US (1) US10301344B2 (pl)
EP (1) EP3202772B1 (pl)
JP (1) JP6761564B2 (pl)
KR (1) KR20170060035A (pl)
CN (1) CN105992769B (pl)
BR (1) BR112017005454A2 (pl)
CA (1) CA2961819C (pl)
ES (1) ES2836099T3 (pl)
HU (1) HUE052588T2 (pl)
PL (1) PL3202772T3 (pl)
PT (1) PT3202772T (pl)
TW (1) TWI680983B (pl)
WO (1) WO2016050134A1 (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020506B (zh) * 2018-02-07 2024-10-11 里亚塔医药公司 新生霉素类似物与脯氨酸的共晶体形式
CN112375087A (zh) * 2020-11-27 2021-02-19 浙江天宇药业股份有限公司 一种脯氨酸恒格列净的合成方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018492B1 (ru) * 2008-08-28 2013-08-30 Пфайзер Инк. Диоксабицикло[3.2.1]октан-2,3,4-триольные производные
NZ602194A (en) * 2010-03-17 2014-10-31 Univ Leuven Kath Storage of respiratory produce
CN102372722A (zh) * 2010-08-10 2012-03-14 江苏恒瑞医药股份有限公司 C-芳基葡萄糖苷衍生物、其制备方法及其在医药上的应用
SG11201500187WA (en) * 2012-07-11 2015-03-30 Osiris Therapeutics Inc Methods of manufacturing cartilage products
US9145434B2 (en) * 2012-07-26 2015-09-29 Boehringer Ingelheim International Gmbh Crystalline complex of 1-cyano-2-(4-cyclopropyl-benzyl)-4-(ss-d-glucopyranos-1-yl)-benzene, methods for its preparation and the use thereof for preparing medicaments
PT2981269T (pt) * 2013-04-04 2023-10-10 Boehringer Ingelheim Vetmedica Gmbh Tratamento de distúrbios metabólicos em animais equinos
CN104031098A (zh) * 2014-06-21 2014-09-10 李友香 降糖药物
CN104017031A (zh) * 2014-06-21 2014-09-03 李友香 降血糖药物和组合物

Also Published As

Publication number Publication date
TWI680983B (zh) 2020-01-01
CN105992769A (zh) 2016-10-05
CA2961819C (en) 2022-11-08
ES2836099T3 (es) 2021-06-24
CA2961819A1 (en) 2016-04-07
US10301344B2 (en) 2019-05-28
JP2017530107A (ja) 2017-10-12
KR20170060035A (ko) 2017-05-31
BR112017005454A2 (pt) 2017-12-12
HUE052588T2 (hu) 2021-05-28
EP3202772A1 (en) 2017-08-09
CN105992769B (zh) 2019-04-02
EP3202772A4 (en) 2017-08-09
PT3202772T (pt) 2020-11-20
TW201612188A (en) 2016-04-01
JP6761564B2 (ja) 2020-09-30
US20170298087A1 (en) 2017-10-19
WO2016050134A1 (zh) 2016-04-07
EP3202772B1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
IL277167B (en) Cyclopropylamines as lsd1 inhibitors
IL277299B (en) Cyclopropylamines as lsd1 inhibitors
HK1231480A1 (zh) 作為 抑制劑的吲唑化合物
HK1231411A1 (zh) 作為 抑制劑的取代的吲唑化合物
IL250642A0 (en) glycosidase inhibitors
HK1244896A1 (zh) 用於手錶的顯示機構
GB201403536D0 (en) Inhibitor compounds
GB201608586D0 (en) Improvements to open display refridgerators
HK1217541A1 (zh) 敲擊鐘錶
HK1207909A1 (en) Reverser for timepiece
EP3466940A4 (en) CRYSTAL SHAPE OF SODIUM-GLUCOSE-COTRANSPORTERS-2-INHIBITOR
PL3202772T3 (pl) Kryształ kompleksu inhibitora l-proliny/glukozy sodowej 2
HK1225814B (zh) 用於諸如鐘錶的便携式物品的顯示裝置
HK1213058A1 (zh) 用於鐘錶的日期顯示裝置
PT3395819T (pt) Forma cristalina de derivado de aminopirano substituído
PL3174849T3 (pl) Synteza pochodnych pirolidyny
HK1243420A1 (zh) 新型蛋白酶體抑制劑的結晶形式
GB201411737D0 (en) Holographic display
AU2014900982A0 (en) Jewellery Box